Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Siltuximab Dose-Escalation in Solid Tumors
NCT00841191Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2009
- Primary completion
- Apr 2011
- Modality
- Monoclonal Antibodies
- Countries
- 5
01
Overview
A Phase 2 trial of siltuximab in solid tumor, ovarian cancer, pancreatic cancer (PC), colorectal cancer (CRC), head and neck cancer (HNC), sponsored by Janssen Pharmaceutical. Started Mar 2009; status: completed.
02
Drugs
siltuximab
03
Conditions
solid tumorovarian cancerpancreatic cancer (PC)colorectal cancer (CRC)head and neck cancer (HNC)
Beyond the preview
Go deeper on NCT00841191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00841191.